Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Elevation lifts HER3 ADC toward clinic with $368M Synaffix deal
Elevation Oncology has agreed to pay Synaffix up to $368 million to access technology for use in its newly nominated HER3 antibody-drug conjugate.
Nick Paul Taylor
Dec 12, 2024 9:19am
Merck ADC RORs into phase 3 with 100% complete response rate
Dec 9, 2024 5:03am
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
AstraZeneca, Daiichi share data behind Dato-DXd do-over
Dec 6, 2024 5:21am
GSK goes East again, snagging option on DualityBio ADC for $30M
Dec 4, 2024 8:20am
Gilead advances ADC dreams with potential $465M deal
Dec 3, 2024 10:54am
